XPhyto Therapeutics Corp.

CNSX: XPHY


Canadian symbol: XPHY.CN
US symbol: XPHYF

Currency in CAD

Valuation Measures

Market Cap (intraday) 5159.5M
Enterprise Value 3160.9M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)340.36
Price/Book (mrq)22.11
Enterprise Value/Revenue 3343.34
Enterprise Value/EBITDA 6-16.70

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3188.00%
S&P500 52-Week Change 35.66%
52 Week High 33.5500
52 Week Low 30.7300
50-Day Moving Average 33.0003
200-Day Moving Average 32.3621

Share Statistics

Avg Vol (3 month) 374.22k
Avg Vol (10 day) 365.5k
Shares Outstanding 554.25M
Float 49.01M
% Held by Insiders 112.20%
% Held by Institutions 10.00%
Shares Short (Jun. 14, 2020) 4180.8k
Short Ratio (Jun. 14, 2020) 42.42
Short % of Float (Jun. 14, 2020) 4N/A
Short % of Shares Outstanding (Jun. 14, 2020) 40.26%
Shares Short (prior month May 14, 2020) 4155.95k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Mar. 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-2,099.21%

Management Effectiveness

Return on Assets (ttm)-61.14%
Return on Equity (ttm)-137.50%

Income Statement

Revenue (ttm)468.63k
Revenue Per Share (ttm)0.01
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)208.12k
EBITDA -9.63M
Net Income Avi to Common (ttm)-10.48M
Diluted EPS (ttm)-0.2170
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.88M
Total Cash Per Share (mrq)0.03
Total Debt (mrq)2.71M
Total Debt/Equity (mrq)37.60
Current Ratio (mrq)2.44
Book Value Per Share (mrq)0.13

Cash Flow Statement

Operating Cash Flow (ttm)-5.62M
Levered Free Cash Flow (ttm)-2.64M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
XPHY.CN
XPhyto Therapeutics
5 months ago
XPHY.CN
XPhyto Therapeutics
5 months ago
XPHY.CN
XPhyto Therapeutics
7 months ago
XPHY.CN
XPhyto Therapeutics
7 months ago
XPHY.CN
XPhyto Therapeutics
7 months ago
XPHY.CN
XPhyto Therapeutics
7 months ago
XPHY.CN
XPhyto Therapeutics
7 months ago
XPHY.CN
XPhyto Therapeutics
7 months ago
XPHY.CN
XPhyto Therapeutics
7 months ago
XPHY.CN
XPhyto Therapeutics
7 months ago
XPHY.CN
XPhyto Therapeutics
7 months ago
XPHY.CN
XPhyto Therapeutics
7 months ago
XPHY.CN
XPhyto Therapeutics
7 months ago
XPHY.CN
XPhyto Therapeutics
7 months ago
XPHY.CN
XPhyto Therapeutics
7 months ago
XPHY.CN
XPhyto Therapeutics
7 months ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
12.20%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
0Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by XPhyto Therapeutics Corp.


XPhyto Therapeutics Corp.: COVID-19 Rapid Screening Test Prototype Validation

XPhyto Therapeutics Corp.: COVID-19 Rapid Screening Test Prototype Validation

Vancouver, British Columbia--(Newsfile Corp. - July 6, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto") is pleased to announce that its exclusive diagnostic partner, 3a-Diagnostics GmbH ("3a"), has confirmed successful function of its novel and proprietary COVID-19 (SARS-CoV-2) RNA probes and its unive... Read More...
XPhyto Therapeutics Corp.: Infectious Disease Oral Screening Test Advancement

XPhyto Therapeutics Corp.: Infectious Disease Oral Screening Test Advancement

Vancouver, British Columbia--(Newsfile Corp. - June 15, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto") is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), has successfully incorporated peptide biosensors into its oral dissolvable thin film ("ODF") platfo... Read More...
XPhyto's Diagnostic Partners Receive BMBF Grant for Infectious Disease Screening Tests

XPhyto’s Diagnostic Partners Receive BMBF Grant for Infectious Disease Screening Tests

Vancouver, British Columbia--(Newsfile Corp. - June 10, 2020) -  XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto") is pleased to announce that its diagnostic partner, 3a-Diagnostics GmbH ("3a") and their contract research collaborators, have received a €254,200 grant from the German Federal Ministry of Educatio... Read More...
Oettinger Brewery Signs Exclusive Agreement with Xphyto for Cannabis-Infused Beverages

Oettinger Brewery Signs Exclusive Agreement with Xphyto for Cannabis-Infused Beverages

VANCOUVER, BC / ACCESSWIRE / May 12, 2020 / XPhyto Therapeutics Corp. (XPHY.CN)(4XT.F)(OTC PINK:XPHYF) ("XPhyto") is pleased to announce that it has signed a standstill agreement and letter of intent (the "Agreement") for cooperation in the field of development, production, and distribution of new cannabis-infused beverages and products w... Read More...
Covid-19 Screening Test, Oral Thin Film Biosensor Products and High-Throughput Biosensor Identification Platform

Covid-19 Screening Test, Oral Thin Film Biosensor Products and High-Throughput Biosensor Identification Platform

VANCOUVER, BC / ACCESSWIRE / April 20, 2020 / XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC PINK:XPHYF) ("XPhyto") is pleased to announce that it has signed a definitive development, technology purchase and licence agreement (the "Agreement") with 3a-Diagnostics GmbH ("3a") for the development and commercialization of real-time, low... Read More...
Exclusive Advisory Agreement Signed for COVID-19 and Host Cell Interactions

Exclusive Advisory Agreement Signed for COVID-19 and Host Cell Interactions

VANCOUVER, BC / ACCESSWIRE / March 25, 2020 / XPhyto Therapeutics Corp. (XPHY.CN) (4XT.F) (OTC PINK:XPHYF) ("XPhyto") is pleased to announce that an exclusive infectious disease advisory agreement (the "Agreement") has been signed between XPhyto and Prof. Dr. Wolfgang Eisenreich. Prof. Dr. Eisenreich brings a unique and highly relevant se... Read More...
Exclusive Strategic Partnership Commenced Between XPhyto Therapeutics and Elite Bavarian Brewing & Beverage Institute Weihenstephan

Exclusive Strategic Partnership Commenced Between XPhyto Therapeutics and Elite Bavarian Brewing & Beverage Institute Weihenstephan

Vancouver, British Columbia--(Newsfile Corp. - February 18, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE:4XT) ("XPhyto") is pleased to announce that its wholly owned German subsidiary, Bunker Pflanzenextrakte GmbH ("Bunker"), has begun its strategic exclusive partnership for research and development of cannabis focused products, spe... Read More...
XPhyto Therapeutics Announces Strategic Supply, Import and Distribution Agreement for the German Cannabis Market

XPhyto Therapeutics Announces Strategic Supply, Import and Distribution Agreement for the German Cannabis Market

Vancouver, British Columbia--(Newsfile Corp. - January 27, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto") is pleased to announce that the Company has signed a three year definitive supply, import and distribution agreement (the "Agreement") with PharmaCielo Ltd. ("PharmaCielo"), one of the largest, highest quality, an... Read More...
Epilepsy Treatment to Be Developed with XPhyto Therapeutics' Oral Thin Film Delivery System

Epilepsy Treatment to Be Developed with XPhyto Therapeutics’ Oral Thin Film Delivery System

Vancouver, British Columbia--(Newsfile Corp. - December 9, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto") is pleased to announce that the development of Epilepsy treatment products using its proprietary oral thin film delivery system will be a priority initiative for 2020. The Company is focusing on generic cannabidi... Read More...
XPhyto Therapeutics Developing Epilepsy Treatment with Oral Thin Film Delivery System

XPhyto Therapeutics Developing Epilepsy Treatment with Oral Thin Film Delivery System

Vancouver, British Columbia--(Newsfile Corp. - December 6, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto") is pleased to announce that the development of Epilepsy treatment products using its proprietary oral thin film delivery system will be a priority initiative for 2020. The Company is focusing on generic cannabidio... Read More...
Xphyto Therapeutics Oral and Transdermal Cannabis Delivery and Dosage Systems

Xphyto Therapeutics Oral and Transdermal Cannabis Delivery and Dosage Systems

Vancouver, British Columbia--(Newsfile Corp. - November 12, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto") is pleased to provide an update on the Company's thin film cannabis delivery and dosage systems in development by XPhyto's wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"). Vektor is a narcotics m... Read More...
XPhyto Therapeutics Engages Global Cannabis Expert for German Operations

XPhyto Therapeutics Engages Global Cannabis Expert for German Operations

Vancouver, British Columbia--(Newsfile Corp. - September 19, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto") is pleased to announce that it has entered into an exclusive two year European consulting agreement (the "Agreement") with Stephen Schroeder, a leading international cannabis expert (the "Consultant"). The Consu... Read More...
XPhyto Therapeutics Closes Acquisition Of Vektor Pharma TF GmbH

XPhyto Therapeutics Closes Acquisition Of Vektor Pharma TF GmbH

VANCOUVER, CANADA / ACCESSWIRE / September 17, 2019 / XPhyto Therapeutics Corp. (CSE:XPHY)(4XT.F) (“XPhyto” or the “Company”) is pleased to announce that it has closed both the definitive share purchase agreement (the “Agreement”) with Vektor Pharma TF GmbH (“Vektor”) and the equipment purchase agreement (the “Equipment Agreement”) entere... Read More...
XPhyto Therapeutics Signs Exclusive German Cannabis Agreement with Elite Bavarian Brewing & Beverage Institute

XPhyto Therapeutics Signs Exclusive German Cannabis Agreement with Elite Bavarian Brewing & Beverage Institute

Vancouver, British Columbia--(Newsfile Corp. - September 9, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto") is pleased to announce that its wholly owned German subsidiary, Bunker Pflanzenextrakte GmbH ("Bunker"), has entered into an exclusive cannabis research and development agreement (the "Agreement") with the chair ... Read More...
XPhyto Therapeutics Enters Exclusive Cannabis Research and Development Agreement with the Technical University of Munich

XPhyto Therapeutics Enters Exclusive Cannabis Research and Development Agreement with the Technical University of Munich

Vancouver, British Columbia--(Newsfile Corp. - August 14, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto") is pleased to announce that its wholly owned German subsidiary, Bunker Pflanzenextrakte GmbH ("Bunker"), has entered into an exclusive cannabis research and development agreement (the "R&D Agreement") with the ... Read More...
Coming Soon.
SymbolExchangePriceChangeAs of
XPHY.CD
Canadian Securities Exchange - CSE Listed
Canadian Securities Exchange - CSE Listed2.94CAD+2.08%
4XT.F
Frankfurt Stock Exchange
Frankfurt Stock Exchange1.93EUR+1.58%
4XT.DE
Xetra
Xetra1.96EUR+1.82%
4XT.BE
Berlin Stock Exchange
Berlin Stock Exchange1.95EUR+3.18%
4XT.MU
Munich Stock Exchange
Munich Stock Exchange1.95EUR-0.26%
4XT.SG
Stuttgart Stock Exchange
Stuttgart Stock Exchange1.94EUR+1.57%
4XT.D
Dusseldorf Stock Exchange
Dusseldorf Stock Exchange1.89EUR-5.03%
4XT.H
Hamburg Stock Exchange
Hamburg Stock Exchange1.88EUR-3.09%
XPHYF.PK
OTC MARKETS GROUP L1 AND L2
OTC MARKETS GROUP L1 AND L22.18USD--

Delayed data (1h)


Share this page